|
|
|
Chirokinetics in Anaphylaxia“In organising this pilot trial into the effects of Chirokinetics in anaphylaxia, it was my hope the results would demonstrate that other people at risk from anaphylactic shock might benefit from this treatment, as my wife and I have. I am very pleased with the enclosed results which clearly show CKT to be both safe and effective, warranting further clinical investigation.” -Mike Collyer (trial organiser) Chirokinetic Therapy (CKT) was developed by David Stevens in 1997. CKT works by identifying and correcting imbalances which have altered the body’s immune response. THE AIM OF THE TRIAL IS TO ESTABLISH THE POSSIBILITY OF DECREASING AN INDIVIDUAL’S REACTIVITY TO THEIR ALLERGEN TO BELOW THE ANAPHYLACTIC THRESHOLD. Trial participants have a previous history of suffering anaphylactic attacks to various substances. All carry an EpiPen and most have been hospitalised on at least one occasion. For the purposes of this investigation their history was considered the most reliable indication of their allergy status. Additionally, several had previous serology examinations. Following a course of CKT treatments participants were required to have a specific Immunoglobulin E examination to determine their allergy status to their known allergen. Conclusion. The results would seem to indicate a significant decrease in reactivity to the specific allergen. Of the ten original participants one was unable to complete the trial and one is awaiting a blood test. Eight have received blood tests the results of which, in all cases, show an SIgE between 0 – 3. Reference range 0 – 6, 0 = negative, 1= borderline, 6= strongly positive. Furthermore five individuals have been accidentally exposed to the specific allergen which previously caused a reaction, without displaying the usual symptoms associated with anaphylaxia. ALL BLOOD TEST RESULTS OBTAINED FROM INDEPENDENT SOURCES |
|---|